Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
GS$901.00+4.17(+0.47%)Goldman Sachs raises 2027 Europe gas price forecasts on MidEast supply, winter risks12:09:21 AM ETGOOGL$280.40-0.85(-0.30%)ANALYSIS -AI-related debt binge may pressure European bond markets12:00:01 AM ETMS$185.73+1.43(+0.78%)BREAKINGVIEWS-Morgan Stanley is a dubious saviour for UBS12:00:00 AM ETCRM$226.00-3.17(-1.38%)Massive News for Salesforce Stock Investors11:45:02 PM ETARM$197.01-8.96(-4.35%)Why Arm Holdings Stock Lost 29% Last Month11:18:59 PM ETORCL$119.50-11.17(-8.55%)UPDATE 6-Oracle taps investors for $20 billion to finance AI expansion10:58:17 PM ETSKHY$148.53-0.68(-0.46%)Samsung and SK Hynix stocks plunge as a $20 billion AI shock rattles markets10:39:42 PM ETC$123.30+0.46(+0.38%)Japanese, Korean, Taiwanese firms' US investment set to keep climbing: Citi10:38:12 PM ETKO$95.96+1.88(+2.00%)Coca-Cola Is Exercising its Pricing Power as Inflation Persists10:35:02 PM ETGOOG$279.21+0.99(+0.36%)Google takes Dreambeans to India in bid to bring AI-generated personal stories to the masses10:30:00 PM ETORCL$119.50-11.17(-8.55%)BRIEF-Oracle Prices $20 Billion Of Common Stock And Senior Notes10:16:41 PM ETORCL$119.50-11.17(-8.55%)Oracle Announces Pricing of $20 Billion of Common Stock and Senior Notes10:10:08 PM ETPLTR$173.00-11.11(-6.03%)Palantir Technologies Inc. (PLTR) Q3 2026 Earnings Call Transcript10:08:30 PM ETIUSG$181.79-1.75(-0.95%)IUSG: Hyperscaler Sell-Off Is Overblown - Buy The Dip9:19:55 PM ETAAPL$328.81-15.82(-4.59%)Apple Forecasts Slower Services Growth as AI Costs Rise9:09:51 PM ETCRDO$140.88-10.11(-6.70%)Credo vs. Sandisk: Which Stock Is the Better Buy for 2027?9:00:02 PM ETAAPL$328.81-15.82(-4.59%)Apple may try to increase revenue by doing8:49:52 PM ETCVX$228.21-7.75(-3.29%)Chevron & Exxon Mobil Stocks Retreat From 52-Week Highs: Buy the Dip?8:21:06 PM ETAAPL$328.81-15.82(-4.59%)Apple Q4 Earnings Call Highlights8:14:45 PM ETPLTR$173.00-11.11(-6.03%)What Palantir Technologies (PLTR) Said on Its Q3 Earnings Call8:14:22 PM ETACN$261.99+2.70(+1.05%)Top 25 Attractive Dividend Stocks For November 20268:10:22 PM ETPLTR$173.00-11.11(-6.03%)Here's why Palantir's stock is down despite a ‘bombastic' quarter7:59:00 PM ETAAPL$328.81-15.82(-4.59%)Apple's iPhone business is booming. Here's why the stock is falling anyway.7:52:00 PM ETAMZN$246.44+5.28(+2.20%)Amazon's Report Passed Both Tests I Set for It. I'd Buy More of the Stock Now.7:47:01 PM ET

ALVO · NASDAQ

Alvotech

$4.85 -0.17 (-3.66%)

Company overview

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira for treating various inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications. It also develops AVT04, a biosimilar to Stelara for inflammatory conditions; AVT06, a biosimilar to Eylea for age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia in the pre-clinical phase for bone-related cancer complications.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Market cap
$1.7B
Employees
1,012
Headquarters
Luxembourg
Website
alvotech.com
CEO
Lisa Graver
Listed
June 16, 2022
P/E
-17.06
Dividend yield
0.00%

Company financials

Revenue
$559M
Gross profit
$343M
Operating income
$77.2M
EBITDA
-$39.1M
Net income
-$80.7M
EPS
-$0.28
Total assets
$1.4B
Total debt
$1.5B
Gross margin
61.35%
Net margin
-14.43%
Earnings yield
-5.86%

Revenue segmentation

By product (FY 2025)

No annual product segmentation.

By region (FY 2025)

Showing FY 2025

Price chart

2.803.774.745.706.67
ALVO 1D NASDAQ O4.75H4.76L4.47C4.48-0.17 (-3.66%)Vol1.12M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
ALVOAlvotech Press release Alvotech to Present at Upcoming Investor Conferences in November GlobeNewswire
ALVOAlvotech Press release Alvotech to Present at Upcoming Investor Conferences in November GlobeNewswire
ALVOAlvotech Press release Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026 GlobeNewswire
ALVOAlvotech Press release Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch GlobeNewswire
ALVOAlvotech Press release Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch GlobeNewswire
ALVOAlvotech Press release Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg GlobeNewswire
ALVOAlvotech Press release Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply GlobeNewswire
ALVOAlvotech Press release FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech's biosimilar to Humira® GlobeNewswire
ALVOAlvotech Stock news Alvotech (NASDAQ:ALVO) Receives $8.50 Average Target Price from Brokerages Defense World
RAPP Stock news Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday Benzinga
ALVOAlvotech Stock news This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Benzinga
ALVOAlvotech Stock news Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
ALVOAlvotech Press release Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations GlobeNewswire
ALVOAlvotech Press release Alvotech to present at upcoming investor conferences in September GlobeNewswire
ALVOAlvotech Stock news Crude Oil Down 3%; XPeng Shares Fall After Q2 Results Benzinga
ALVOAlvotech Stock news Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday Benzinga
ALVOAlvotech Press release Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets GlobeNewswire
ALVOAlvotech Stock news Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts Seeking Alpha
ALVOAlvotech Stock news Alvotech (ALVO) Q2 2026 Earnings Call Transcript Seeking Alpha
ALVOAlvotech Stock news Alvotech Q2 Earnings Call Highlights MarketBeat
See more
FAQ

Questions about Alvotech

What does Alvotech do?
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira for treating various inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications. It also develops AVT04, a biosimilar to Stelara for inflammatory conditions; AVT06, a biosimilar to Eylea for age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia in the pre-clinical phase for bone-related cancer complications.
What is ALVO's market cap?
Alvotech (ALVO) is a listed stock with a live quote. The latest market cap on this page is $1.7B.
Where is Alvotech headquartered?
Alvotech is headquartered in Luxembourg.
How do I get ALVO news from the API?
Call GET /v1/news?tickers=ALVO. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ALVO news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ALVO, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ALVO price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs